Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

The National Medical Products Administration (NMPA) in China has approved Sanofi SA's (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura.

Benzinga • Dec 11, 2025

Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases

Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year Cablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura.

GlobeNewsWire • Dec 11, 2025

Sanofi's Bleeding-Disorder Treatments Get Approval in China

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.

WSJ • Dec 11, 2025

InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders

SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a strategic equity investment and research collaboration with Sanofi. The agreement with Sanofi includes the right of first negotiation for InduPro's bispecific PD-1 agonist program, which is currently in preclinical development for the treatment of autoimmune and infl.

Business Wire • Dec 10, 2025

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public health experts fear will undermine decades of public health advances.

Reuters • Dec 5, 2025

Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”).

GlobeNewsWire • Dec 4, 2025

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

LONDON--(BUSINESS WIRE)-- #AI--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius' AI/ML-driven antibody design capabilities with Sanofi's expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success.

Business Wire • Dec 4, 2025

3 Large Drug Stocks to Watch as the Industry Shows Some Recovery

In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

Zacks Investment Research • Dec 4, 2025

Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 4, 2025